SCHEMBL15919224

SCHEMBL15919224

C=CCN(CC=C)Cc1ccccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.49
HTT P42858 2/20 0.49
PYCR1 P32322 1/20 0.49
IDO1 P14902 3/20 0.43
PNMT P11086 1/20 0.43
TAAR1 Q96RJ0 3/20 0.41
AOC3 Q16853 1/20 0.39
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR1D P28221 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR1E P28566 1/20 0.38
SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11667015 0.85 ALDH1A1 (0.56) ALDH1A1LMNAHTTPYCR1BCHE
SCHEMBL31438230 0.83 IDO1 (0.54) ALDH1A1LMNAPYCR1IDO1PNMT
SCHEMBL10882173 0.77 TAAR1 (0.47) TAAR1AOC3BCHEHTR1AADRA2A
SCHEMBL10974173 0.76 ALDH1A1 (0.49) ALDH1A1LMNAHTTPYCR1BCHE
SCHEMBL11526249 0.76 MAPT (0.50) ALDH1A1LMNAHTTPYCR1TAAR1
SCHEMBL4942839 0.76 ALDH1A1 (0.53) ALDH1A1LMNAHTTIDO1TAAR1
SCHEMBL5611653 0.76 ALDH1A1 (0.49) ALDH1A1LMNAHTTPYCR1PNMT
SCHEMBL1110914 0.76 ALDH1A1 (0.49) ALDH1A1LMNAHTTPYCR1BCHE
SCHEMBL16715934 0.75 BCHE (0.54) ALDH1A1LMNAHTTPYCR1IDO1
SCHEMBL248417 0.74 IDO1 (0.50) ALDH1A1LMNAHTTIDO1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170057907-A1 METHOD FOR THE REDUCTIVE AMINATION OF ALDEHYDES BASF SE (DE) 2017-03-02 US disclosed
US-9040751-B2 Method for producing ring-halogenated N,N-dialkylbenzylamines LANXESS DEUTSCHLAND GMBH (US) 2015-05-26 US disclosed
US-20140221691-A1 METHOD FOR PRODUCING RING-HALOGENATED N,N-DIALKYLBENZYLAMINES LANXESS DEUTSCHLAND GMBH (DE) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221691-A1 METHOD FOR PRODUCING RING-HALOGENATED N,N-DIALKYLBENZYLAMINES NPM1, UGT1A6, NNMT ALDH1A1 1159/4885LMNA 2147/4885HTT 210/4885
US-20170057907-A1 METHOD FOR THE REDUCTIVE AMINATION OF ALDEHYDES AOX1, ADH5, AOC2 ALDH1A1 26/4885LMNA 2284/4885HTT 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.